Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Weight Maintenance in Adolescents With Obesity
NCT06571383Phase 4Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2024
- Primary completion
- Nov 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 4 trial of semaglutide in obesity, sponsored by Novo Nordisk. Started Sep 2024; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06571383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571383.